Sunday, April 13, 2014
Saturday, March 22, 2014
"Video maps growth in doctors, nurses and healthcare professionals using Twitter since its launch in 2006 to 2014. Data sourced using Creation Pinpoint, the world's largest research tool for learning from healthcare professionals in public social media."
Wednesday, March 19, 2014
|Sodium valproate is a common mood stabilizer (Photo credit: Wikipedia)|
- sodium and T-type calcium channel blocker
- an NMDA receptor-channel blocker (?helpful in hyperalgesia)
- alters GABA (distinctively selective for midbrain), dopamine and serotonin transmission
Tuesday, March 18, 2014
|A mirror box used for treating phantom limbs, developed by V.S. Ramachandran. (Photo credit: Wikipedia)|
"Whether the phantom is in the hand or the foot the principle of mirror box therapy is still the same. In this video soldier Bryan Wagner talk us through his phantom and how mirror box therapy help him cope with the pain."
Link to full article and video
Monday, March 3, 2014
The WPCA - Global Atlas of Palliative Care:
"Published jointly by the World Health Organization and the Worldwide Palliative Care Alliance, the Atlas is the first document to map the need for and availability of palliative care globally.
Using maps, graphs and case studies, and drawing on a wealth of resources, the Atlas addresses the following questions:
- What is palliative care?
- Why is palliative care a human rights issue?
- What are the main diseases requiring palliative care?
- What is the need for palliative care?
- What are the barriers to palliative care?
- Where is palliative care currently available?
- What are the models of palliative care worldwide?
- What resources are devoted to palliative care?
- What is the way forward"
Read the full article here
Tuesday, February 25, 2014
"The American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
Key recommendations for secondary prevention of recurrent VTE19"
- LMWH is the preferred approach for the initial 5 to 10 days of anticoagulant treatment of the cancer patient with established VTE
- LMWH given for 6 months is also the preferred approach for long-term anticoagulant therapy. Vitamin K antagonists with a targeted INR of 2 to 3 are acceptable for long-term therapy when LMWH is not available
- After 6 months, indefinite anticoagulant therapy should be considered for selected patients with active cancer, such as those with metastatic disease and those receiving chemotherapy
- The insertion of a vena cava filter is only indicated for patients with contraindications to anticoagulant therapy and in those with recurrent VTE despite adequate long-term therapy with LMWH
- For patients with CNS malignancies, anticoagulation is recommended for established VTE as described for other patients with cancer. Careful monitoring is necessary to limit the risk of hemorrhagic complications. Anticoagulation should be avoided in the presence of active intracranial bleeding, recent surgery, preexisting bleeding diathesis such as thrombocytopenia (platelet count <50 coagulopathy="" font="" l="" or="">50>
- For elderly patients, anticoagulation is recommended for established VTE as described for other patients with cancer. Careful monitoring and dose adjustment is necessary to avoid excessive anticoagulation and further increase in the risk of bleeding
For full article including great summary charts and diagrams as well as other key player guidelines, click here.
Saturday, February 22, 2014
Personalized Cancer Treament, From Just a Blood Sample - The Crux | DiscoverMagazine.com:
"A technique being developed by San Diego–based Epic Sciences can determine whether a cancer patient is an appropriate candidate for a drug, and even whether the drug is losing its efficacy.
In research presented last month at the Personalized Medicine World Conference in Palo Alto, CA, Epic described how their technology can be used to reliably pick out rare cells from a blood sample. In the case of cancer, these rare, circulating tumor cells could one day tell an oncologist not only whether a patient’s cancer has returned, but also whether it’s growing resistant to the current treatment regimen—something only expensive scans and invasive biopsies can do with any accuracy today."
Read the full article here